(1120) Feasibility of Blood-Based Biomarkers for Lung Cancer Prediction: Current Advancements & Challenges

Introduction: The Nodify Lung test is a recently introduced blood test that evaluates the risk of malignancy in pulmonary nodules. It involves a two-step process, starting with the Cdt Test which identifies autoantibodies associated with lung cancer. If positive, further diagnostic tests and treatment can be provided. The second step, the Xl2 test, detects surface proteins that indicate the likelihood of a nodule being benign. This test aims to correlate the results of the Nodify Lung test with biopsy findings. Lung cancer is the most common cancer over 1.5 million people are diagnosed each year.

Methods: Retrospective chart review has been carried out for all patients with solitary pulmonary nodules who underwent Nodify Lung test (CDT and Xl2) from January 2019 to November 2022 at the specified research site. Statistical analysis will be done using IBM-SPSS Statistics, Version 27.

Results: A study included 84 subjects, with 50% males and 50% females, mean age 69 years. All patients underwent Nodify Lung test (CDT, Xl2, or both). Smoking history: >50 pack years: 23.81% (20); < 50 pack years: 52.38% (44); never smoked: 23.81% (20). Symptoms recorded: dyspnea, cough, chest pain, wheezing, weight loss. asymptomatic: 35.71% (30); symptomatic: 64.29% (54). Dyspnea: 24.07% (38); cough: 24.07% (13); wheezing: 1.85% (1); chest pain: 1.85% (1); weight loss: 1.85% (1).
Out of 84 participants, 17 had intermediate and high post-Nodify risk test results indicating antibodies related to lung cancer. Among them, 12 had intermediate risk and underwent biopsy (8 diagnosed with lung cancer). 4 patients refused biopsy. Additionally, 5 patients with high risk underwent biopsy (3 diagnosed with lung cancer). 2 patients refused biopsy. In total, 6 patients declined biopsy, while 11 patients underwent biopsy and were diagnosed with lung cancer. Types of lung cancer diagnosed: adenocarcinoma (5), non-small cell lung cancer (3), squamous cell lung cancer (2), carcinoid tumor (1).

Conclusions: Nodify Lung is an effective blood test for assessing the risk of malignancy in solitary pulmonary nodules. It enhances diagnostic accuracy when combined with critical thinking and clinical skills. The test improves the detection of malignant nodules, enabling timely diagnosis and treatment of lung cancer.